Frequency Therapeutics reports trial fail and lays off over half of staff — stock capsizes – Endpoints News February 13, 2023
G1 Therapeutics abandons PhIII colorectal cancer trial after disappointing overall response rates – Endpoints News February 13, 2023
New Chad Mirkin-founded biotech hopes to make more effective cancer vaccines – Endpoints News January 30, 2023January 30, 2023
Moderna jumps into pivotal pack with promising RSV data as big rivals face off in megablockbuster race – Endpoints News January 18, 2023January 18, 2023
AbbVie opts out of industry trade groups PhRMA, BIO plus Business Roundtable – Endpoints News December 16, 2022December 16, 2022
As Novo Nordisk begins PhII sickle cell trial, it snags a later-stage blood disorder drug in $1.1B Forma buy – Endpoints News September 1, 2022September 1, 2022
Gilead’s Trodelvy scores ‘surprise’ OS win in metastatic breast cancer, but data will wait for an upcoming conference – Endpoints News August 16, 2022August 16, 2022
Novartis’ $650M cash bet on a near-term FDA OK for BeiGene’s China PD-1? It just got delayed indefinitely – Endpoints News July 14, 2022July 14, 2022
AbbVie dumps an early-stage drug in $225M Alzheimer’s alliance with Alector – Endpoints News July 9, 2022July 9, 2022
Senators again point to AbbVie as a poster child for reform. Only this time Dems are targeting a low, low tax rate – Endpoints News July 8, 2022July 8, 2022